DexCom (NasdaqGS:DXCM) is seeing higher adoption of its continuous glucose monitoring systems among patients using GLP-1 drugs, as physicians pair both therapies for diabetes care. The company is ...

Three of the top diabetes tech companies put forward new clinical data this week, making the case for their continuous glucose monitors and insulin pumps as they look to expand their reac | Three ...

SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today its next-generation Dexcom G7 CGM System ...

New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. Ontario residents eligible for ODB and ...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the FDA has cleared the next-generation ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The FDA has granted clearance to a next-generation ...

Dexcom has received approval from the FDA for a new version of its smartphone connected Dexcom Share platform that will eliminate the docking cradle and allow a patient's continuous glucose monitor ...

It takes two: After making its commercial debut early this year, Dexcom’s latest continuous glucose monitor is wrapping up 2023 by connecting with its first automated insulin pump partner, courtesy of ...

DexCom is a major player in the continuous glucose monitoring space, with steadily growing revenues and a breakout year in 2020. DXCM's market cap valuation has reached $40 billion, leading to high ...

DexCom's DXCM shares have risen 6.9% since Tuesday last week, while yesterday’s after-market movement took the rally to nearly 8%. Last week, the company presented a positive picture for its ...